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Abstract
Background: TANDEM is a randomised controlled trial of a complex healthcare intervention to improve the
psychological and physical health of people living with chronic obstructive pulmonary disease (COPD) and anxiety
and/or depression. Based on health psychology theory set out in a logic model, respiratory health professionals
were recruited and trained to deliver a cognitive behavioural approach intervention (The TANDEM intervention)
under the supervision of senior cognitive behavioural practitioners. Here, we describe the protocol for the process
evaluation commissioned alongside the trial. A realist approach that includes attention to describing contexts and
mechanisms has been adopted.
Methods: We set up a multi-disciplinary team to develop and deliver the process evaluation. The mixed-methods
design incorporates quantitative process data; monitoring of intervention fidelity; qualitative interviews with
patients, carers, health professionals (facilitators) and clinical supervisors about their perspectives on acceptability of
the intervention; and exploration with all stakeholders (including management/policy-makers) on future
implementation. Normalisation process theory (NPT) will inform data collection and interpretation with a focus on
implementation. Quantitative process data will be analysed descriptively. Qualitative interview data will be analysed
before the trial outcomes are known using analytic induction and constant comparison to develop themes.
Findings from the different elements will be reported separately and then integrated.
Conclusion: Detailed description and analysis of study processes in a research trial such as TANDEM enables
research teams to describe study contexts and mechanisms and to examine the relationship with outcomes. In this
way, learning from the trial goes beyond the randomised control trial (RCT) model where effectiveness is prioritised
and makes it possible to explore issues arising for post-trial study implementation.
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Background
Chronic obstructive pulmonary disease (COPD) is a
complex long-term condition (LTC) associated with
considerable morbidity and mortality. It has a global
prevalence of 11.7% in adults aged over 30 years [1]. It is
considered to be a neglected disease [2] despite being
the third leading cause of death worldwide, the fifth big-
gest cause of death in the UK [3], and the ninth cause of
disability-adjusted life years [4]. Pulmonary rehabilitation
(PR) is an effective therapeutic approach for people with
COPD [5, 6]. However, both referrals from health pro-
fessionals and attendance at PR courses by patients are
sub-optimal [7]. COPD often co-exists with other LTCs,
including anxiety (10–50%) [8, 9], and depression (30%)
[8], which affect hospital admissions, quality of life and
self-efficacy [10, 11]. The evidence for optimal ap-
proaches to managing psychological comorbidities in
COPD is not conclusive, and there are few evidence-
based care pathways for anxiety and depression in
people with COPD [12]. Psychological therapies such as
cognitive behavioural therapy (CBT) are proposed as
potential treatments for patients living with LTCs
such as COPD with co-morbid anxiety and/or depres-
sion [13–15]. Research suggests that the beneficial ef-
fects of psychological treatment for anxiety and
depression on its own in COPD are limited and
therefore studies have reported linking psychological
treatment with physical activity, lifestyle and self-
management support interventions to improve patient
outcomes [16]. Despite much discussion about the
need to provide patient-centred care for people with
LTCs that integrates mental and physical health,
health professionals often find addressing psycho-
logical aspects challenging [17, 18].
This paper presents the protocol for a process evalu-
ation being undertaken in parallel to a trial evaluating a
tailored intervention using a cognitive behavioural ap-
proach (CBA) incorporating self-management skills which
precedes, links with, and optimises the benefits of cur-
rently offered PR, in patients with COPD and depression
and/or anxiety. The intervention incorporates training
and supervision of respiratory healthcare professionals to
deliver five to eight individual CBA sessions to patients
whilst awaiting PR. The multi-centre, pragmatic, rando-
mised controlled trial (RCT), including an internal pilot,
will assess whether receiving the intervention (TANDEM)
prior to routine PR improves anxiety and/or depression in
people with moderate to very severe COPD (GOLD cri-
teria [19]) and mild to moderate anxiety and/or depres-
sion. The trial will also assess if the intervention improves
attendance and completion of PR. A parallel economic
evaluation will be undertaken. The main trial protocol has
been published [20].
The TANDEM randomised controlled trial
We hypothesise that the TANDEM intervention will im-
prove anxiety and/or depression and consequently en-
courage uptake and completion of PR.
TANDEM trial objectives are:
1. To undertake a RCT of the TANDEM intervention
to examine the effectiveness of this intervention on
clinical outcomes compared to usual care (i.e. the
offer of PR alone).
2. To examine the effect of the TANDEM
intervention (which is directed at patients) on their
carers (where appropriate).
3. To determine the cost-effectiveness of the
TANDEM intervention from a National Health Ser-
vice (NHS) and personal social services perspective.
4. To conduct a process evaluation to inform the
implementation of the TANDEM intervention if the
trial is positive, or assist interpretation of the
findings if it is negative.
TANDEM is a complex intervention meaning that it is
composed of multiple interacting components [21]. The
multi-level intervention integrates both CBA training of
health professionals and their delivery of CBA to pa-
tients. We have developed an intervention logic model
[22] which maps out a causal chain for the problem
under investigation and identifies the intervention mecha-
nisms, which aspects will be changed, and how (see Fig. 1).
The model uses an intervention based on Beck’s cognitive
behaviour therapy model for managing anxiety and depres-
sion [23], as well as self-management training informed by
Bandura’s social cognitive theory [24, 25], and Leventhal’s
self-regulation theory [26]. The logic model is based on the
premise that the way in which individuals with COPD think
about their illness has an influence on how they be-
have and feel. Change targeted at cognitive, behav-
ioural or symptom level will improve emotional
outcomes and self-management making it more likely
that people will attend PR [27].
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Respiratory healthcare professionals (including physio-
therapists, nurses, and occupational therapists), termed
TANDEM facilitators, have been recruited, trained and
are supervised to deliver tailored, manualised sessions,
that draw on the principles of cognitive behavioural
therapy, to NHS patients living with COPD and co-
morbid mild to moderate anxiety and/or depression. We
describe this as a cognitive behavioural approach (CBA)
intervention [27]. TANDEM facilitators deliver five to
eight (with nine maximum weekly CBA sessions to allow
for a missed session, e.g. due to illness), each lasting 40–
60min, in a location preferred by the patient, and if the
patient decides to attend PR the facilitators provide fur-
ther telephone support sessions before starting PR and
continuing to two weeks following completion of PR. Fa-
cilitators receive telephone clinical supervision by a
trained cognitive behavioural practitioner. Patients (and
their carers) have been recruited from 12 participating
National Health Service (NHS) Trusts partnered with
five NHS Clinical Commissioning Groups (CCGs). Facil-
itators have been recruited among the participating
study sites and from neighbouring NHS organisations
across England.
Process evaluation
Process evaluation is viewed as an essential element in
trials of complex interventions [28]. It is used to assess
fidelity, the quality of implementation, causal mecha-
nisms, and to identify contextual factors associated with
variation in outcomes [21]. A process evaluation can
provide additional information for interpreting trial re-
sults and making decisions about whether the interven-
tion is likely to work in a wider context [29]. If the
intervention is found not to work, detailed description of
the processes involved in delivery can help to explain
whether this was due to problems with the intervention
or failure to implement the intervention as planned [30].
The value of concurrently evaluating implementation
alongside effectiveness in a hybrid design has been pro-
posed [31], and this is typically done in a process evalu-
ation. TANDEM is an example of a hybrid type 1 design
which involves testing a clinical intervention whilst
Fig. 1 Logic model for TANDEM intervention
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gathering information on delivery during the effective-
ness trial and/or on its potential for implementation in
the real-world [31]. The TANDEM process evaluation
was set up after initial development work and formative
evaluation, involving pre-pilot and pilot studies, which is
reported by Steed et al. [27].
Process evaluation methods
Underpinning theory and considerations for the process
evaluation
Complex interventions are now presented as interactions of
theory, context and implementation, rather than a set of
mechanisms of change across multiple domains [32]. Our
process evaluation, in line with MRC guidance [33], is
broadly informed by the principles of realist evaluation [34,
35]. Realist evaluation is an evaluation framework that at-
tends to what it is about an intervention that works, for
whom it works, and in what circumstances. It examines
phenomena in relation to how context, mechanism and
outcome are configured as patterns [34]. All Interventions
are underpinned by theoretical assumptions about change
and this may involve more than one theory, especially in
complex interventions. We held a workshop to discuss and
agree conceptual models, creating a multi-dimensional
framework that aims to make the different elements visible
in order to maximise the field of vision in terms of breadth
and depth, in turn enabling fuller engagement with the
complex systems in which complex interventions are
undertaken [36]. The conceptual framework for the
TANDEM process evaluation can be seen in Fig. 2.
Theory informs the TANDEM process evaluation in
three main ways:
➢ Realist evaluation principles of context, mechanism,
outcome underpin the overall approach to our process
evaluation design (understanding how the intervention
works)
➢ Programme theory using psychological theory is set
out as a logic model linking causal mechanisms (theory
of change)
➢ Normalisation process theory (NPT) will be used to
consider implementation
Fig. 2 TANDEM process evaluation conceptual framework
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In addition the process evaluation, similarly to the
TANDEM intervention and study, is underpinned by a
strong patient centred ethos [37].
An intervention can be considered as an event in a dy-
namic complex system [38], where viewing the interven-
tion dynamically affects how the reach and effectiveness
can be improved. There has been an emphasis on en-
gaging from the early stages of study development with
those who would receive the intervention (patients and
carers) and those who would deliver it (health care pro-
fessionals) in order to optimise participant engagement
with the study tools and the relevance of the interven-
tion to real-world implementation. Patient and public
involvement in TANDEM, including the process evalu-
ation, can be seen in Fig. 3. The trial participants (pa-
tients, carers, health care professionals) are treated as
active agents, who interact with the intervention mecha-
nisms within a specified set of system conditions and
shape the systems in which they are nested.
When considering outcomes, we aim to understand
how participants interact with the intervention mecha-
nisms so that change is generated. For example, people
living with COPD often experience multimorbidity and
have complex lives that affect their experience of care
[39, 40], meaning that it can be difficult to isolate the
impact of the COPD. It is also not possible to separate
the facilitators’ experiences of delivering the intervention
from the contexts in which they work including their
professional identity. We need therefore to describe con-
texts, how contexts influence system change and how
the intervention modifies the context. Potentially salient
contextual influences on effectiveness and implementa-
tion that we have identified for the TANDEM trial are
as follows: facilitators’ professional practice; facilitator
training; patient-facilitator relationship; facilitator super-
vision; patient (and carer where relevant) complex lives,
policy-level priorities and organisational stakeholders’
perspectives on the delivery context. These will be ex-
plored using qualitative methods which are described
below.
Explication of conceptual frameworks is key to guiding
the post-trial implementation process [41]; however, al-
though formal and informal theory in implementation
studies is viewed as important, it is often poorly de-
scribed and under-recognised [42]. NPT challenges re-
searchers to consider how their intervention might
Fig. 3 Patient and public involvement in the TANDEM study
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become embedded or ‘normalised’ (or not) into routine
practice [41, 43]. In NPT, the work involved in imple-
mentation is investigated by focusing on: how people
make sense of the intervention (coherence); how people
participate in the intervention (cognitive participation);
how they act collectively (collective action); and how
they reflect and monitor what is happening (reflexive
monitoring) [44].
Aims and objectives
The overall aim of our process evaluation is to describe
and understand the processes by which the trial is con-
ducted (specifically including fidelity and acceptability to
recipients and professionals) and to consider the effect
of these on the outcomes of the study. The process
evaluation will also inform the implementation of the
TANDEM intervention if the trial outcome is positive,
or assist in the interpretation of findings if it is negative.
The objectives address: acceptability, fidelity and
implementation.
Specific objectives are:
1. To assess the acceptability of the intervention to
patients and carers, including consideration of:
content (in session, home practice); therapeutic
alliance; and practicalities (location, timing).
2. To assess the acceptability of the intervention to
facilitators and supervisors delivering the
intervention.
a. Patient-facing CBA sessions including content,
structure, logistics, telephone support and
integration of components.
b. Facilitator training including content, logistics,
supervision, perceived confidence to deliver the
CBA sessions.
c. Management of workload.
d. Supervisors’ training and workload.
3. To monitor the delivery of the intervention through
assessment of fidelity.
a. Was the facilitator training delivered as
intended with respect to professional
competence?
b. Were the CBA sessions delivered as intended
with respect to adherence and competency?
4. To consider the feasibility of implementing the
intervention with respect to:
a. The recruitment, training and retention of
facilitators and organisation of clinical
supervision.
b. Rates of completed delivery of at least two CBA
sessions (pre-determined estimate of minimal
clinically important “dose” of intervention) per
patient.
c. Numbers of patients seen by facilitators and
numbers of sessions delivered to patients and
reasons for intervention non-attendance/ no de-
livery of sessions.
d. Intervention drop-out or disruption to delivery
and reason for drop out or disruption.
5. To explore the experiences and perspectives of
patients, carers, facilitators, and supervisors
regarding the intervention and post-trial
implementation.
a. What are patients, carers, facilitators and
supervisors’ experiences of the intervention and
what are their views about its potential impact
on health and quality of care?
b. What are the barriers and facilitators to
implementation and how do these vary
according to context and/or other factors?
c. Were there any unexpected consequences?
6. To explore the views of organisational stakeholders
regarding post-trial implementation of the
intervention.
a. What are the barriers and facilitators to
implementation and how do these vary according to
context and/or other factors?
b. What resources and partnerships are necessary for
implementation?
c. To understand whether adaptations to the
intervention are necessary depending on the clinical
context in which it takes place e.g. if the
intervention is delivered through primary care,
secondary care or solely via PR services.
Research design and methods
This is a mixed-methods study using quantitative and
qualitative methods. We are collecting quantitative and
qualitative data from the intervention arm of the trial (and
quantitative data from the control arm). The process
evaluation lead (MK) is not involved in the design or de-
livery of the trial itself. RS, AB, KM and VR are involved
in trial recruitment and data collection. The different
types of data collected are described below and are sepa-
rated for practical purposes but will be integrated and
drawn upon in complementary ways in order to address
the process evaluation aims and objectives. For example,
qualitative data from patient and facilitator interviews may
be used to triangulate with findings from the fidelity
analysis.
Quantitative process data
Quantitative data are being collected throughout the
multi-level intervention in order to understand whether
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delivering the intervention was feasible, assess the work-
load required for delivery, and how this may have varied
from the trial protocol. Structured data will be presented
descriptively and will be collected via:
 Facilitator recruitment, training attendance and
training completion rates.
 Facilitator retention and caseloads of facilitators.
 Data logs on uptake, attendance, cancelled/re-
scheduled appointments and completion of CBA
sessions by patients.
 CBA content logs at the end of each face-to face patient
session and analysis of audio-recordings of sessions.
 Subsequent attendance at PR (including number of
PR sessions attended)
 Telephone support sessions by facilitator.
Qualitative data collection
Qualitative research can explore complex phenomena
and areas less amenable to quantitative research [45]
and aid understanding of the processes involved in both
intervention and evaluation. Central to our process
evaluation is collecting qualitative interview data that
will allow us to describe, review and interpret the trial
processes, including mechanisms and contexts, by gain-
ing in-depth understanding of the perspectives of re-
search participants. The qualitative data are being
collected via three sub-studies: experiences and views of
patients and carers on receiving the intervention (RS,
AB, KM), experiences and views of facilitators and su-
pervisors on training and delivering the CBA sessions
(SN, AM) and views of organisational stakeholders (clin-
ical commissioners, GPs, PR specialists, nurses, psychol-
ogists) on the implementation context (VW, VR). To
reduce the risk of bias, interviewers are not interviewing
participants they have recruited to the study. Details of
the qualitative data collection and outline topic guides
can be seen in Table 1.
Interviews are being undertaken by telephone or in
person depending upon the preference of the research
participant and the COVID-19 pandemic restrictions.
Topic guides for the interviews with patients, carers, fa-
cilitators and supervisors are based on those used in the
developmental and pilot phases. The topic guide for the
organisational stakeholders draws on issues arising in
discussions within the trial team. With a view to gaining
Table 1 Qualitative data collection methods
Sample Main issues addressed by topic guide
Patients 5 participants who completed face to face TANDEM sessions
(after 6-month follow-up assessment)
5 participants who dropped out of TANDEM (< 4 CBA sessions)
(after 6-month follow-up assessment)
5 participants who completed TANDEM CBA sessions and PR
programme (after 6/12-month follow-up assessment)
5 participants who completed TANDEM but dropped out or
did not attend PR (after 12-month follow-up assessment)
• Current experience of COPD/breathlessness
• Experience of being in the TANDEM study
• Relationship and working with the TANDEM facilitator
• Experience of attending PR
• Suggested improvements to the TANDEM experience
• Perspectives on receiving TANDEM as part of routine care
Carers of intervention
participants
5 (after 6-month follow-up assessment) • Relationship with patient/role
• Understanding of TANDEM
• Perspectives on CBA sessions
• Experience of care role in the study
• Any observed improvements in patient’s condition/quality
of life
Facilitators Up to 14
All facilitators to be invited, but aim for range of professional
group and number of patients seen
• Training sessions
• CBA sessions with patients
• Supervision
• Professional identity
• Perspectives on post-trial implementation
Clinical supervisors Up to 4
All invited
• Training
• Clinical supervision sessions
• Logistics of organising supervision sessions




Up to 20 interviews
Range of organisational context and roles
• Organisation and role
• Issues faced in delivering and improving COPD services
• Perspectives on the value of PR for people with COPD
• Understanding of TANDEM
• Views on the TANDEM approach to care
• Perceived differences with current care approaches for
COPD
• Perspectives on post-trial implementation of TANDEM
• Facilitators and barriers for implementation
• Commissioning
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an understanding of issues for implementation, topic
guides have also been informed by the key NPT con-
structs of coherence, cognitive participation, collective
action and reflexive monitoring [44]. Through this user-
centred approach, we expect to gain insight into con-
textual influences and the facilitators and barriers to
post-trial implementation. The NPT concepts will sup-
port our analysis and help to identify implementation
challenges and areas where further evaluation is needed.
The topic guides provide structure and aim to elicit par-
ticipant experiences and perspectives in the context of
their lives and work roles. Open questions are used to
explore issues in the terms of participants and to allow
for unexpected issues to emerge.
Sampling frames have been drawn up based on a pur-
posive sampling approach aiming for maximum vari-
ation [46] to gain a full range of views. Sampling is being
reviewed during data collection and data analysis so that
if unexpected themes emerge additional perspectives can
be sought. If saturation is reached data collection will
stop [47].
Data analysis
Quantitative process data will be analysed and presented
using simple descriptive statistics (e.g. counts and pro-
portions). Qualitative data will initially be analysed the-
matically using an inductive approach and constant
comparison [48]. Group discussion in research teams
improves the rigour and quality of qualitative research
[49], so our analysis will be a reflexive, iterative process
involving review and multidisciplinary discussion. NVivo
12 software will be used to assist in the organisation and
analysis of the data. A thematic narrative will be con-
structed for each sub-study.
Our approach is to undertake theoretically informative
research in addition to theoretically informed research
[50]. Further analysis will therefore be undertaken, with
second level themes identified and explored in the light
of relevant theory and research literature [50, 51]. Data
will also be interpreted drawing upon NPT resources
such as the NPT toolkit [52] to assist interpretation of
the data regarding post-trial implementation.
Fidelity assessment
Assessment of intervention fidelity follows the American
Behaviour Change Consortium framework [53] and aims
to find out whether the intervention was delivered as
intended and the quantity (dose) of intervention imple-
mented. Should the trial outcome be negative fidelity as-
sessment makes it possible to understand whether it is
the intervention that is ineffective or if delivery failed
[30]. Complex interventions usually undergo some tai-
loring/adaptation when delivered in different contexts.
Capturing what is delivered in practice with reference to
the theory of the intervention can enable evaluators to
understand the core elements and where more flexibility
may be allowed. Analysis focuses on what was delivered
and how it was delivered, including training and support,
communication and logistics, and how these structures
interact with the implementer facilitators’ attitudes and
circumstances to shape the intervention.
Fidelity will be assessed at two levels:
 The delivery of the 3-day facilitator training was re-
corded. Preliminary assessment of facilitators’ skills
was made on days 2 and 3 of the training where pos-
sible using the IAPT low intensity practitioner as-
sessment manual (based on Blackburn’s Cognitive
Therapy Scale [54] by at least two trainers.
 Audio-recordings of all intervention sessions will be
made. A random 25% sample of recorded sessions
across all 25 CBA interventions, and a smaller
sample of 10% of CBA entire interventions will be
coded with respect to facilitator adherence to the
manual and competence in trained skills. The
fidelity assessment framework is reported in detail
by Steed et al (Steed L, Wileman V, Sohanpal R,
Kelly M, Pinnock H, Taylor S. Assessing fidelity in
the TANDEM study: Strategies for enhancement
and a protocol for assessment, in preparation).
Integrating results of analysis
The different evaluation elements will be reported separ-
ately and then integrated before the trial results are
known. The main trial findings will be analysed inde-
pendently of the process evaluation findings. Once both
analyses are complete the analyses will be combined.
We aim to produce a high-quality, integrated evalu-
ation of the trial processes informed by a clear concep-
tual framework. We will ensure rigour across our
analyses by being transparent, maintaining a clear ac-
count of the procedures used in an audit trail. We are
addressing validity by providing evidence to support our
interpretations and providing context. We are also
undertaking a comprehensive analysis of each data set.
Workshops with patients and carers will be set up, de-
pending on their preference and convenience, to con-
sider interpretation of the trial findings in the light of
the process evaluation analysis. Workshops will also be
held with facilitators to discuss findings from the process
evaluation and explore issues around implementation,
including CBA training and engaging patients.
Conclusion
Providing detailed description and analysis of study pro-
cesses in a research trial such as TANDEM can enable
research teams to examine and interpret how study con-
texts and mechanisms contribute to outcomes. In this
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way, learning from the trial goes beyond the RCT model
where effectiveness is prioritised. It also makes it pos-
sible to explore issues arising for post-trial study
implementation.
As with many process evaluations, in designing our
study, we have had to think strategically and prioritise
areas to cover due to limited resources. We have pro-
duced an integrated, organic design (rather than a linear
framework) that aims to optimise the usefulness of the
TANDEM trial findings. We will be in a position to cap-
ture ‘messy realities’ in our process evaluation [32] that
will provide insights into the complex and pragmatic is-
sues emerging and how to respond to them. This in-
cludes consideration of context at an early stage to
optimise implementation [41]. A specific—and unex-
pected—issue arising during the TANDEM trial is the
impact of the COVID-19 pandemic on patients (many at
high risk), stretched healthcare professionals and
diverted research capacity.
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